Search 

Arthur Roach is representing both Parkinson's UK and Chord Therapeutics at this meeting.

Arthur Roach is Director of Research at Parkinson’s UK, where he is responsible for the strategy to convert the demands and priorities of people living with Parkinson’s into better treatments and a deeper understanding of the condition.  In the current five-year strategic period Parkinson’s UK is investing £40 million in university research grants, international collaborations and data sharing, drug discovery and early clinical development of new treatments, and promoting the greater involvement and participation of people with Parkinson’s in research.  He brings to this role over 25 years of experience of research into Parkinson’s, Alzheimer’s, multiple sclerosis and other neurodegenerative diseases and the discovery and development of new treatments (DuPont, Bristol-Myers Squibb, Merck Serono).

Arthur is also the founder of Chord Therapeutics, a single-asset virtual biotech dedicted to clinical development of CRD1 as a new treatment for neuromyelitis optica and other rare autoimmune neurological conditions.  Chord  is seeking financing for a three-year programme to establish clinical proof of concept in two indications.